[go: up one dir, main page]

BR9508115A - Composto composição farmacêutica e processos para tratar deficiências imunológicas ou controlar o aumento de câncer e para aumentar o número de linfócitos t citotóxicos em mamíferos - Google Patents

Composto composição farmacêutica e processos para tratar deficiências imunológicas ou controlar o aumento de câncer e para aumentar o número de linfócitos t citotóxicos em mamíferos

Info

Publication number
BR9508115A
BR9508115A BR9508115A BR9508115A BR9508115A BR 9508115 A BR9508115 A BR 9508115A BR 9508115 A BR9508115 A BR 9508115A BR 9508115 A BR9508115 A BR 9508115A BR 9508115 A BR9508115 A BR 9508115A
Authority
BR
Brazil
Prior art keywords
lymphocytes
cytotoxic
mammals
processes
increase
Prior art date
Application number
BR9508115A
Other languages
English (en)
Inventor
Salam Kandhim
Guy Ely
Yves St-Denis
Christopher Penney
Timothy Connolly
Boulos Zacharie
Lyne Gagnon
Giorgio Attardo
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of BR9508115A publication Critical patent/BR9508115A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9508115A 1994-06-22 1995-06-21 Composto composição farmacêutica e processos para tratar deficiências imunológicas ou controlar o aumento de câncer e para aumentar o número de linfócitos t citotóxicos em mamíferos BR9508115A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26402894A 1994-06-22 1994-06-22
PCT/CA1995/000356 WO1995035297A1 (en) 1994-06-22 1995-06-21 Novel substituted purinyl derivatives with immunomodulating activity

Publications (1)

Publication Number Publication Date
BR9508115A true BR9508115A (pt) 1998-11-03

Family

ID=23004250

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508115A BR9508115A (pt) 1994-06-22 1995-06-21 Composto composição farmacêutica e processos para tratar deficiências imunológicas ou controlar o aumento de câncer e para aumentar o número de linfócitos t citotóxicos em mamíferos

Country Status (16)

Country Link
US (2) US5994361A (pt)
EP (1) EP0766683A1 (pt)
JP (1) JP4151765B2 (pt)
CN (1) CN1051083C (pt)
AU (1) AU2666795A (pt)
BR (1) BR9508115A (pt)
FI (1) FI965040A7 (pt)
HU (1) HUT77780A (pt)
IL (1) IL114266A0 (pt)
MX (1) MX9700211A (pt)
NO (1) NO317552B1 (pt)
NZ (1) NZ287827A (pt)
PL (1) PL184342B1 (pt)
RU (1) RU2191189C2 (pt)
WO (1) WO1995035297A1 (pt)
ZA (1) ZA955131B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
AU2583901A (en) * 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
WO2002043618A1 (en) * 2000-12-01 2002-06-06 Targent, Inc. Methods for contemporaneous administration of levamisole and 5-fluorouracil
JP4381804B2 (ja) * 2001-06-27 2009-12-09 サイクラセル リミテッド ２，６，９−置換プリン誘導体及び増殖性疾患の治療におけるその使用
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
JP4397691B2 (ja) * 2001-10-30 2010-01-13 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
CN100345545C (zh) * 2003-06-18 2007-10-31 中国科学院上海药物研究所 6－氨基－α(R)－羟基－9H－嘌呤－9－丁酸乙酯的免疫抑制作用
KR20060070572A (ko) * 2003-09-18 2006-06-23 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ90-저해제로서의 신규 헤테로시클릭 화합물
MXPA06005910A (es) 2003-11-25 2006-08-23 3M Innovative Properties Co Sistemas de anillo imidazo sustituido y metodos.
MXPA06011080A (es) 2004-03-26 2007-04-16 Astrazeneca Ab Compuesto de 8-oxoadenina 9-sustituido.
ZA200701781B (en) * 2004-09-03 2008-11-26 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
EP1869027A4 (en) 2005-03-30 2010-06-23 Conforma Therapeutics Corp ALKYNYL-PYRROLOPYRIMIDINES AND CORRESPONDING ANALOGS AS HSP90 INHIBITORS
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939198A4 (en) * 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939201A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
US20090118263A1 (en) * 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
WO2007034882A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007034916A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
CN101379195B (zh) * 2005-12-20 2012-05-09 艾德拉药物股份有限公司 含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US8067413B2 (en) * 2007-03-19 2011-11-29 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators
WO2008114006A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
WO2008114819A1 (ja) * 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
US8436178B2 (en) * 2007-05-08 2013-05-07 Astrazeneca Ab Imidazoquinolines with immuno-modulating properties
CN104119336B (zh) * 2007-10-05 2016-08-24 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
KR20100125245A (ko) * 2008-01-17 2010-11-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 아데닌 화합물의 제조 방법
WO2009091031A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
RU2424241C2 (ru) * 2008-12-29 2011-07-20 Сергей Павлович Сяткин Производные ксантина, обладающие антипролиферативной активностью, модуляторы клеточной дифференцировки, способ замедления скорости пролиферации опухолевых клеток, способ индукции дифференциации в клетках
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
JP5913093B2 (ja) 2009-05-21 2016-04-27 アストラゼネカ アクチボラグ 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用
WO2011068233A1 (en) * 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
RU2492825C2 (ru) * 2010-10-18 2013-09-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения рака сигмовидной кишки у женщин по сидоренко ю.с.
CN103370317B (zh) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
EP2651943B1 (en) 2010-12-17 2017-03-22 Sumitomo Dainippon Pharma Co., Ltd. Purine derivatives
SG187271A1 (en) * 2011-07-07 2013-02-28 Agency Science Tech & Res Anti-amyloidogenic, alpha-helix breaking ultra-small peptide therapeutic
JP6184423B2 (ja) 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
WO2017040234A1 (en) * 2015-08-31 2017-03-09 3M Innovative Properties Company IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS
AU2016317637B2 (en) * 2015-08-31 2019-01-31 Solventum Intellectual Properties Company Guanidine substituted imidazo[4,5-c] ring compounds
WO2017191297A1 (en) * 2016-05-04 2017-11-09 Bci Pharma Adenine derivatives as protein kinase inhibitors
PE20220166A1 (es) * 2019-03-05 2022-01-28 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad
WO2025262243A1 (en) * 2024-06-19 2025-12-26 Invios Gmbh Thieno- and thiazolopyrimidine-2,6-diones and use thereof as immunomodulators

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3165520A (en) * 1965-01-12 Certificate of correction
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
AU515553B2 (en) * 1976-03-01 1981-04-09 The Wellcome Foundation Limited Purine derivatives
DE3028273A1 (de) * 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
AU564576B2 (en) * 1981-09-24 1987-08-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Purine derivatives
US4602089A (en) * 1982-03-12 1986-07-22 Newport Pharmaceuticals, Inc. Process for preparing purine compounds
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
NO161116C (no) * 1982-10-14 1989-07-05 Wellcome Found Analogifremgangsmaate for fremstilling av antiviralt virksomme purinderivater.
JPS5998099A (ja) * 1982-11-05 1984-06-06 Fujisawa Pharmaceut Co Ltd 新規テトラヒドロフランカルボン酸誘導体、その製造法およびその医薬組成物
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
DK302883D0 (da) * 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
US4663326A (en) * 1985-04-04 1987-05-05 Warner-Lambert Company Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
IN164556B (pt) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
IT1213495B (it) * 1986-09-17 1989-12-20 Sigma Tau Ind Farmaceuti Processo per la preparazione dell'alfa-n-[(ipoxatin-9-il)pentilossicarbonil-]arginina
IT1215339B (it) * 1987-01-14 1990-02-08 Co Pharma Corp Srl Procedimento per la preparazione di 9-(idrossialchil)-ipoxantine
US4782062A (en) * 1987-05-11 1988-11-01 Merck & Co., Inc. 9-(2-hydroxymethyl)cycloalkylmethyl) guanines
US5214048A (en) * 1987-05-19 1993-05-25 Nippon Kayaku Kabushiki Kaisha Oxetanocins
IT1223604B (it) * 1987-12-24 1990-09-29 Co Pharma Corp Srl Derivati purinici ad azione farmacologica
US5015739A (en) * 1988-04-22 1991-05-14 Schering Corporation Processes for preparation of cyclopentyl purine derivatives
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5369098A (en) * 1988-07-18 1994-11-29 E. R. Squibb & Sons, Inc. Hydroxymethyl cyclobutyl purines
EP0363320A3 (de) * 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
US5332744A (en) * 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IT1241452B (it) * 1990-06-28 1994-01-17 Sigma Tau Ind Farmaceuti Derivati oligopeptidici dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono
US5470857A (en) * 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
IT1244501B (it) * 1991-03-22 1994-07-15 Sigma Tau Ind Farmaceuti Derivati amminoacilici e oligopeptidici dell'allopurinolo dotati di attivita' immunostimolante e composizioni farmaceutiche che li contengono
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
CN1137274A (zh) * 1993-11-12 1996-12-04 默里尔药物公司 用作免疫抑制剂的6-氧代-核苷
US5516905A (en) * 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections

Also Published As

Publication number Publication date
NO317552B1 (no) 2004-11-15
US5994361A (en) 1999-11-30
US6110923A (en) 2000-08-29
WO1995035297A1 (en) 1995-12-28
IL114266A0 (en) 1995-10-31
JPH10501533A (ja) 1998-02-10
AU2666795A (en) 1996-01-15
HUT77780A (hu) 1998-08-28
CN1157618A (zh) 1997-08-20
FI965040L (fi) 1997-02-21
CN1051083C (zh) 2000-04-05
RU2191189C2 (ru) 2002-10-20
FI965040A0 (fi) 1996-12-16
ZA955131B (en) 1997-03-24
NO965394D0 (no) 1996-12-13
EP0766683A1 (en) 1997-04-09
NO965394L (no) 1997-02-21
HU9603492D0 (en) 1997-02-28
JP4151765B2 (ja) 2008-09-17
PL184342B1 (pl) 2002-10-31
FI965040A7 (fi) 1997-02-21
NZ287827A (en) 1999-02-25
MX9700211A (es) 1998-01-31
PL317902A1 (en) 1997-04-28

Similar Documents

Publication Publication Date Title
BR9508115A (pt) Composto composição farmacêutica e processos para tratar deficiências imunológicas ou controlar o aumento de câncer e para aumentar o número de linfócitos t citotóxicos em mamíferos
BR9602856A (pt) Composição de polissacarídeo enxertado método para o tratamento de artrite em mamíferos e para a preparação de polissacarídeo enxertado com antioxidante
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
ITMI922233A1 (it) Prodotti farmaceutici per curare malattie tumorali e procedimento per la loro preparazione
FI931085A7 (fi) Kasvainten vastaisia koostumuksia ja hoitomenetelmiä
BR9604950A (pt) Composição farmacêutica contendo n-clorofenil carbamatos n-clorofeniltiocarbamatos e derivados de n-fosfonoglicina para inibir o crescimento de cânceres e vírus em mamíferos
IL97463A0 (en) Pharmaceutical composition for treating emotional numbness
FI955426A7 (fi) Pintakäsittelytuotteet ja menetelmät niiden valmistamiseksi
EE03312B1 (et) Asendatud arüülalküültioalküültiopüridiinid Helicobacter bakterite tõrjeks, nende valmistamismeetod ja kasutamine ravimite valmistamiseks
CZ63895A3 (en) 5-vinyl-quinolone-carboxylic, 5-vinyl-naphthyridon-carboxylic, +5-ethinyl-quinolone-carboxylic and 5-ethinyl-naphthyridon-carboxylic acids, process of their preparation, medicaments in which said compounds are comprised and their use
ZA967319B (en) Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
AU2742395A (en) Therapeutic or dietetic composition in the form of medicinal gel for the administration to pets
EP0279425A3 (en) Use of benzothiazepine derivatives, in particular diltiazem, in the manufacture of medicaments to protect lymphocytes
EP0343671A3 (en) Pharmaceutical composition for the treatment of skin wounds
ZA903044B (en) Interferon for the use in the prevention or treatment of swine pneumonia or related bacterial diseases
GB8908843D0 (en) Improvements in or relating to the treatment of surfaces
GB2255718B (en) Pharmaceutical composition for treating bacterial and / or viral infection
FR2636239B1 (fr) Composition desinfectante pour la prevention de la mammite subclinique chez les ruminants
GB9413939D0 (en) Pharmaceutical composition for the treatment of chronic skin ulcers
RU96114373A (ru) Способ лечения легкого течения острой пневмонии
ZA893275B (en) Pharmaceutical composition for the treatment of migraine and the like
ITMI931765A0 (it) Composizione anticancerogena per filtri di sigarette o simili e filtritrattati con detta composizione
LV5035A3 (lv) Preparats govju endometritu profilaksei un arstesanai
MX9201735A (es) Composicion farmaceutica para el tratamiento y profilaxis de inflamacion y dolor en mamiferos.
IL77075A (en) Pharmaceutical compositions comprising chromium for use in the treatment of atherosclerosis

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 15A ANUI DADE.

B25D Requested change of name of applicant approved

Owner name: SHIRE BIOCHEM INC. (CA)

Free format text: ALTERADO DE: BIOCHEM PHARMA INC.

B25G Requested change of headquarter approved

Owner name: SHIRE BIOCHEM INC. (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080155015/RJ DE 16/12/2008.

B25D Requested change of name of applicant approved

Owner name: SHIRE CANADA INC. (CA)

Free format text: ALTERADO DE: SHIRE BIOCHEM INC.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AO NAO CUMPRIMENTO DO DESPACHO 24.3 NA RPI 2054 DE 18/05/2010 E COMPROVAR RECOLHIMENTO DA16A, 17A E 18A ANUIDADES.